You are here: Home » 0 » » Archives for 0st

DigiAsia Corp. Appoints Andreas Gregori to its AI Strategic Advisory Board

~ The Addition Strengthens the Delivery of Meaningful AI Fintech Solutions for its Enterprise Clients ~

NEW YORK, Aug. 20, 2024 (GLOBE NEWSWIRE) — DigiAsia Corp. (NASDAQ: FAAS) (“DigiAsia” or the “Company”), a leading Fintech as a Service (“FaaS”) ecosystem provider, today announced that Andreas Gregori, a current member of DigiAsia’s board of directors and highly experienced business executive and entrepreneur, has been appointed as an advisor to its recently established AI strategic advisory board. Mr. Gregori is a seasoned commercial leader with a digital and customer–first mindset. His deep knowledge of leveraging technology and AI in meaningful ways will propel the Company as it rapidly integrates AI solutions to enhance its Fintech offerings for enterprise clients and partners in Indonesia and beyond.

Mr. Gregori has over 15 years of global C–suite experience within leading technology and telecommunications companies with vast experience driving growth through bold commercial and technology programs for multi–billion–dollar organizations and start–ups in both mature and emerging markets. Since 2019, Mr. Gregori has served as President of Axiom D Inc., where he devises new digital revenue streams and business models around innovative value propositions, customer value management and data monetization. Previously, Mr. Gregori served as Chief Marketing Officer and Chief Digital Officer of Indosat Ooredoo, Indonesia’s second largest telecommunications provider, where he led the successful company transformation to establish itself as a leading digital telco in Indonesia. Mr. Gregori has a Ph.D. in Computer Science and Artificial Intelligence from Technische Universitat Berlin, Germany, and an M.S. in Computer Science from Technische Universitat Darmstadt, Germany.

Prashant Gokarn, CEO of DigiAsia, commented, “We are honored that industry veteran Andreas has further dedicated his time and experience to our AI advisory team. Andreas’ leadership, technological acumen and customer–first mindset have proven to drive operational growth through bold innovations. His expertise will be instrumental as we accelerate the development and deployment of innovative AI fintech solutions that deliver significant value to our clients and contribute to sustained economic growth.”

Andreas Gregori added, “I am excited to deepen my involvement with DigiAsia as a member of its AI strategic advisory board. DigiAsia already powers significant parts of the digital value chain for Indonesia’s leading enterprises, and I am eager to contribute to the development of its next generation fintech solutions. By leveraging AI and our access to Nvidia’s cutting–edge GPUs, we can create powerful tools to drive enterprise growth across the region.”

About DigiAsia

DigiAsia is a leading Fintech as a Service (FaaS) provider in Indonesia and nearby emerging markets and digitizing finance across the commerce ecosystem operating as a B2B2X model. DigiAsia’s fintech architecture offers municipalities and small and medium enterprise business (SME) comprehensive embedded finance APIs to streamline processes across the commerce value chain. DigiAsia’s embedded fintech solutions equally address democratizing digital finance access that supports financial inclusion of underbanked merchants and consumers in emerging markets resulting in growth for enterprise business. The suite of B2B2X solutions provided by DigiAsia include, but are not limited to, cashless payments, digital wallets, digital banking, remittances and banking licenses. DigiAsia has recently established a strategic initiative to develop its embedded FaaS enterprise solution with AI capabilities in Southeast Asia, India, and the Middle East, with plans for global expansion. For more information, please visit DigiAsia’s Corporate website here or Investor Relations website here.

Forward–Looking Statements:

This press release may contain forward–looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe”, “expect”, “anticipate”, “project”, “targets”, “optimistic”, “confident that”, “continue to”, “predict”, “intend”, “aim”, “will” or similar expressions are intended to identify forward–looking statements. All statements other than statements of historical fact are statements that may be deemed forward–looking statements. These forward–looking statements including, but not limited to, statements concerning DigiAsia and the Company’s operations, financial performance and condition are based on current expectations, beliefs and assumptions which are subject to change at any time. DigiAsia cautions that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors such as government and stock exchange regulations, competition, political, economic and social conditions around the world including those discussed in DigiAsia’s Form 20–F under the headings “Risk Factors”, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Business Overview” and other reports filed with the Securities and Exchange Commission from time to time. All forward–looking statements are applicable only as of the date it is made and DigiAsia specifically disclaims any obligation to maintain or update the forward–looking information, whether of the nature contained in this release or otherwise, in the future.

DigiAsia Company Contact:
Subir Lohani
Chief Financial Officer and Chief Strategy Officer
646–480–0142

Investor Contact:
MZ North America
Email: FAAS@mzgroup.us


GLOBENEWSWIRE (Distribution ID 9217207)

Entera Bio to Participate in Upcoming Investor and Scientific Conferences

JERUSALEM, Aug. 20, 2024 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today announced that management will be participating in the following investor and scientific conferences:

H.C. Wainwright 26th Annual Global Investment Conference (Presentation and 1×1)

Date and Time: September 9, 2024 at 7am ET
Location: Virtual, September 9–11, 2024

American Society for Bone and Mineral Research 2024 Annual Meeting (Poster and 1×1)

Date and Time: Saturday, September 28, 2024, 2:15 – 3:45PM 
Location: In person, September 26–29, 2024 Toronto, Canada

7th Annual Evercore ISI HealthCONx Conference (Fireside Chat and 1×1)

Date and Time: December 4, 2024 at 3:25–3:45PM in Track 2 – Sevilla A
Location: In person, December 3–5, 2024 Coral Gables, Florida

About Entera Bio

Entera is a clinical stage company focused on developing oral peptide or protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The Company leverages on a disruptive and proprietary technology platform (N–Tab™) and its pipeline includes five differentiated, first–in–class oral peptide programs, expected to enter the clinic (Phase 1 to Phase 3) by 2025. The Company’s most advanced product candidate, EB613 (oral PTH (1–34)), is being developed as the first oral, osteoanabolic (bone building) once–daily tablet treatment for post–menopausal women with low BMD and high–risk osteoporosis. A placebo controlled, dose ranging Phase 2 study of EB613 tablets (n= 161) met primary (PD/bone turnover biomarker) and secondary endpoints (BMD). Entera is preparing to initiate a Phase 3 registrational study for EB613 pursuant to the FDA’s qualification of a quantitative BMD endpoint which is expected to occur by January 2025. The EB612 program is being developed as the first oral PTH(1–34) tablet peptide replacement therapy for hypoparathyroidism. Entera is also developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity; and first oral GLP–2 peptide tablet as an injection–free alternative for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health. For more information on Entera Bio, visit www.enterabio.com or follow us on LinkedIn, Twitter, Facebook, Instagram.

Cautionary Statement Regarding Forward Looking Statements

Various statements in this press release are “forward–looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this press release regarding our prospects, plans, financial position, business strategy and expected financial and operational results may constitute forward–looking statements. Words such as, but not limited to, “anticipate,” “believe,” “can,” “could,” “expect,” “estimate,” “design,” “goal,” “intend,” “may,” “might,” “objective,” “plan,” “predict,” “project,” “target,” “likely,” “should,” “will,” and “would,” or the negative of these terms and similar expressions or words, identify forward–looking statements. Forward–looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward–looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved.

Important factors that could cause actual results to differ materially from those reflected in Entera’s forward–looking statements include, among others: changes in the interpretation of clinical data; results of our clinical trials; the FDA’s interpretation and review of our results from and analysis of our clinical trials; unexpected changes in our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; the potential disruption and delay of manufacturing supply chains; loss of available workforce resources, either by Entera or its collaboration and laboratory partners; impacts to research and development or clinical activities that Entera may be contractually obligated to provide; overall regulatory timelines; the size and growth of the potential markets for our product candidates; the scope, progress and costs of developing Entera’s product candidates; Entera’s reliance on third parties to conduct its clinical trials; Entera’s expectations regarding licensing, business transactions and strategic collaborations; Entera’s operation as a development stage company with limited operating history; Entera’s ability to continue as a going concern absent access to sources of liquidity; Entera’s ability to obtain and maintain regulatory approval for any of its product candidates; Entera’s ability to comply with Nasdaq’s minimum listing standards and other matters related to compliance with the requirements of being a public company in the United States; Entera’s intellectual property position and its ability to protect its intellectual property; and other factors that are described in the “Cautionary Statements Regarding Forward–Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Entera’s most recent Annual Report on Form 10–K filed with the SEC, as well as the company’s subsequently filed Quarterly Reports on Form 10–Q and Current Reports on Form 8–K. There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera. Therefore, no assurance can be given that the outcomes stated or implied in such forward–looking statements and estimates will be achieved. Entera cautions investors not to rely on the forward–looking statements Entera makes in this press release. The information in this press release is provided only as of the date of this press release, and Entera undertakes no obligation to update or revise publicly any forward–looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.


GLOBENEWSWIRE (Distribution ID 9217620)